Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation

Research output: Contribution to journalArticle

Abstract

Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalActa medica Okayama
Volume73
Issue number1
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Hepatitis B Surface Antigens
End Stage Liver Disease
Liver
Liver Transplantation
Vaccination
Hepatitis B virus
Liver Cirrhosis
Tissue Donors
Acute Liver Failure
Hepatitis B
Hepatitis B Antibodies
Hepatitis B Vaccines
Immunoglobulins
Viruses
Cercopithecine Herpesvirus 1
Costs and Cost Analysis
Synthetic Vaccines
Antibody Formation
Vaccines
Recurrence

Keywords

  • acute liver failure
  • hepatitis B
  • hepatitis B vaccine
  • liver cirrhosis
  • liver transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{f5255759a24847bc85fc189f68125f73,
title = "Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation",
abstract = "Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29{\%} (8/28) of the LC-B group, 88{\%} (7/8) of the ALF-B group, and 44{\%} (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.",
keywords = "acute liver failure, hepatitis B, hepatitis B vaccine, liver cirrhosis, liver transplantation",
author = "Ailee Ikeda and Akinobu Takaki and Tetsuya Yasunaka and Atsushi Oyama and Takuya Adachi and Nozomu Wada and Hideki Ohnishi and Fusao Ikeda and Hidenori Shiraha and Kazuhiro Yoshida and Takashi Kuise and Daisuke Nobuoka and Ryuichi Yoshida and Yuzo Umeda and Takahito Yagi and Toshiyoshi Fujiwara and Hiroyuki Okada",
year = "2019",
month = "2",
day = "1",
doi = "10.18926/AMO/56457",
language = "English",
volume = "73",
pages = "41--50",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Predictive Factors for Successful Vaccination Against Hepatitis B Surface Antigen in Patients Who Have Undergone Orthotopic Liver Transplantation

AU - Ikeda, Ailee

AU - Takaki, Akinobu

AU - Yasunaka, Tetsuya

AU - Oyama, Atsushi

AU - Adachi, Takuya

AU - Wada, Nozomu

AU - Ohnishi, Hideki

AU - Ikeda, Fusao

AU - Shiraha, Hidenori

AU - Yoshida, Kazuhiro

AU - Kuise, Takashi

AU - Nobuoka, Daisuke

AU - Yoshida, Ryuichi

AU - Umeda, Yuzo

AU - Yagi, Takahito

AU - Fujiwara, Toshiyoshi

AU - Okada, Hiroyuki

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.

AB - Post-orthotopic liver transplantation (OLT) hepatitis B recurrence is well-controlled with a nucleos(t)ide analogue and hepatitis B immunoglobulin (HBIG) combination, but the high cost and the potential risk of unknown infection associated with HBIG remain unresolved issues. Low-cost recombinant hepatitis B virus (HBV) vaccine administration is a potential solution to these problems. We retrospectively analyzed the rate and predictive factors of HBV vaccine success in 49 post-OLT patients: liver cirrhosis-type B (LC-B), n=28 patients; acute liver failure-type B (ALF-B), n=8; and non-HBV-related end-stage liver disease (non-B ESLD) who received a liver from anti-hepatitis B core antibody-positive donors, n=13. A positive anti-hepatitis B surface antibody response was achieved in 29% (8/28) of the LC-B group, 88% (7/8) of the ALF-B group, and 44% (4/9) of the adult non-B ESLD group. All four non-B ESLD infants showed vaccine success. The predictive factors for a good response in LC-B were young age, marital donor, and high donor age. ALF-B and non-B ESLD infants are thus good vaccination candidates. LC-B patients with marital donors are also good candidates, perhaps because the donated liver maintains an efficient immune memory to HBV, as the donors had already been infected in adulthood and showed adequate anti-HBV immune responses.

KW - acute liver failure

KW - hepatitis B

KW - hepatitis B vaccine

KW - liver cirrhosis

KW - liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=85062423025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062423025&partnerID=8YFLogxK

U2 - 10.18926/AMO/56457

DO - 10.18926/AMO/56457

M3 - Article

VL - 73

SP - 41

EP - 50

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -